Literature DB >> 12406873

An intronic polymorphism in the PAR-1 gene is associated with platelet receptor density and the response to SFLLRN.

Annabelle Dupont1, Pierre Fontana, Christilla Bachelot-Loza, Jean-Luc Reny, Ivan Biéche, Florence Desvard, Martine Aiach, Pascale Gaussem.   

Abstract

Protease-activated receptor 1 (PAR-1), the main thrombin receptor on vascular cells, plays a key role in platelet activation. We examined the range of PAR-1 expression on platelets, obtained twice, 1 week apart, from 100 healthy subjects and found a 2-fold interindividual variation in receptor numbers (95% CI = 858-1700). Because PAR-1 density was stable with time (r(2) = 76%, P <.001), we sought a genetic explanation for the observed variability. To validate this approach, we also analyzed the alpha(2)beta(1) genotype according to receptor density and platelet mRNA expression data. We found that the number of PAR-1 receptors on the platelet surface is associated with the intervening sequence IVSn-14 A/T intronic variation. The number of receptors was also found to govern the platelet response to the SFLLRN agonist, in terms of aggregation and P-selectin expression. The T allele (allelic frequency, 0.14) can be considered as an allele with decreased expression, because it was associated with lower PAR-1 expression on the platelet surface and with a lower response to SFLLRN. The IVSn-14 A/T intronic variation may therefore be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406873     DOI: 10.1182/blood-2002-07-2149

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  The genetics of normal platelet reactivity.

Authors:  Thomas J Kunicki; Diane J Nugent
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 2.  Genetically Determined Platelet Reactivity and Related Clinical Implications.

Authors:  Teresa Strisciuglio; Giuseppe Di Gioia; Chiara De Biase; Massimiliano Esposito; Danilo Franco; Bruno Trimarco; Emanuele Barbato
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-05-19

Review 3.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

Review 4.  The domino effect triggered by the tethered ligand of the protease activated receptors.

Authors:  Xu Han; Marvin T Nieman
Journal:  Thromb Res       Date:  2020-08-04       Impact factor: 3.944

Review 5.  Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.

Authors:  Teresa Strisciuglio; Danilo Franco; Giuseppe Di Gioia; Chiara De Biase; Carmine Morisco; Bruno Trimarco; Emanuele Barbato
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 6.  Proteinase activated-receptors-associated signaling in the control of gastric cancer.

Authors:  Silvia Sedda; Irene Marafini; Roberta Caruso; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 7.  Genetic dissection of platelet function in health and disease using systems biology.

Authors:  Wadie F Bahou
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-09       Impact factor: 3.722

8.  Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.

Authors:  G Lurje; H Husain; D G Power; D Yang; S Groshen; A Pohl; W Zhang; Y Ning; P C Manegold; A El-Khoueiry; S Iqbal; L H Tang; M A Shah; H-J Lenz
Journal:  Ann Oncol       Date:  2009-07-21       Impact factor: 32.976

9.  Alternative mRNA is favored by the A3 haplotype of the EPCR gene PROCR and generates a novel soluble form of EPCR in plasma.

Authors:  Beatrice Saposnik; Elodie Lesteven; Anna Lokajczyk; Charles T Esmon; Martine Aiach; Sophie Gandrille
Journal:  Blood       Date:  2007-12-11       Impact factor: 22.113

10.  Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects.

Authors:  Julie H Oestreich; Steven R Steinhubl; Suellen P Ferraris; Charles D Loftin; Wendell S Akers
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.